Division of Biochemistry and Structural Biology, CSIR- Central Drug Research Institute, Jankipuram Vistar, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
Division of Biochemistry and Structural Biology, CSIR- Central Drug Research Institute, Jankipuram Vistar, Lucknow 226031, India.
Cell Immunol. 2022 May;375:104529. doi: 10.1016/j.cellimm.2022.104529. Epub 2022 Apr 26.
Visceral leishmaniasis is one of the deadliest parasitic diseases in the world. In the absence of an efficient and cost-effective drugs, development of an effective vaccine is the need of the day. In spite of several efforts, a successful vaccine against the disease has been elusive. We have evaluated immunoprophylactic efficacy of recombinant dipeptidycarboxypeptidase (rLdDCP), predominantly expressed in amastigotes, in chronic hamster model. rLdDCP induced in vitro lymphoproliferation and NO production in cured hamsters. Immunization with rLdDCP alone, or with BCG, caused significant reduction in parasite load suggesting strong protective response. The molecule also augmented the CMI response as depicted by an increased lymphocyte proliferation, NO production, DTH responses and increased levels of IgG2 in immunized hamsters. The vaccinated hamsters exhibited a surge in IFN-γ, TNF-α, IL-12 and iNOS levels but down-regulation of IL-10 and IL-4. Thus, the results suggest the potentiality of the rLdDCP as a strong candidate vaccine.
内脏利什曼病是世界上最致命的寄生虫病之一。由于缺乏高效且经济有效的药物，因此开发有效的疫苗是当务之急。尽管进行了多次努力，但针对该疾病的成功疫苗仍难以实现。我们已经在慢性仓鼠模型中评估了主要在无鞭毛体中表达的重组二肽羧基肽酶（rLdDCP）的免疫预防功效。rLdDCP 在已治愈的仓鼠中诱导体外淋巴细胞增殖和 NO 产生。单独用 rLdDCP 或用卡介苗（BCG）免疫可显著降低寄生虫载量，表明具有强大的保护作用。该分子还增强了细胞介导的免疫反应，表现为淋巴细胞增殖、NO 产生、迟发型超敏反应和免疫仓鼠中 IgG2 水平的增加。接种疫苗的仓鼠表现出 IFN-γ、TNF-α、IL-12 和 iNOS 水平的激增，但 IL-10 和 IL-4 的下调。因此，这些结果表明 rLdDCP 作为一种强有力的候选疫苗具有潜力。
